“…No treatments other than plasma exchange have been documented to be effective nor are approved for treatment of acute TTP, but the ability of rituximab to prevent relapsing TTP is currently tested 3,4 . The investigational anti–von Willebrand factor (VWF) aptamer ARC1779 effectively inhibits VWF activity in plasma samples of TTP patients and thus shear‐dependent platelet (PLT) function 5 . As this would offer a new treatment possibility for a critically ill patient, refractory to standard care, we explored the pharmacokinetics, pharmacodynamics, safety, and efficacy of ARC1779.…”